Key result
Advances in vector development and genetic payload design have improved the efficiency of gene delivery to the heart in preclinical models, leading to a new wave of clinical trials.
This review highlights advances in vector design and genetic payloads that are enabling the translation of cardiac gene therapy from preclinical models to clinical trials for myocardial disease.
Answers are grounded in this paper and cite their sources.
Cardiac gene therapy trials warrant monitoring; extends preclinical vector gains but leaves open clinical efficacy and safety.
Effective clinical delivery of gene therapy to the heart requires understanding and design of complex biological systems to deliver therapeutic gene expression. The development of vectors that specifically target the myocardium, in particular bioengineered recombinant viruses, has improved the efficiency of gene delivery to the heart. These tools, coupled with advances in selection and design of the genetic payload, have led to effective cardiac gene therapy in preclinical models. This technology is currently translating to the clinic with a new wave of gene therapy trials for myocardial disease.
No takes yet. Share an insight, caveat, or question.
Lyon et al. (2007) conducted a review in Myocardial disease. Gene therapy was evaluated. Advances in vector development and genetic payload design have improved the efficiency of gene delivery to the heart in preclinical models, leading to a new wave of clinical trials.
Synapse has enriched 10 related papers. Consider them for comparative context: